Hims & Hers Health has launched its Peptides+ longevity platform across the United States through its telehealth service, according to a Simply Wall St analysis published on Yahoo Finance. The offering bundles compounded peptide and nutrient therapies into a subscription-style program with at-home blood collection and ongoing clinical oversight.
The named ingredients are sermorelin, NAD+, glutathione, vitamin B-12 and L-carnitine. Sermorelin is the only peptide in that list, and the rest are the standard furniture of the longevity clinic menu, which tells you something about how the category is being assembled.
A subscription tier, not a product
The structure is the interesting part. Peptides+ is described as a personalized program layered onto Care+ lab panels and at-home diagnostics, which makes it a recurring specialty rather than a single line item on a storefront.
That matters commercially because Hims & Hers already reaches nearly 3 million subscribers across multiple conditions, per the analysis. Adding a higher-complexity tier to an existing telehealth and lab stack is a cheaper growth path than acquiring new customers, and the company is clearly betting that longevity is the tier people will pay up for.
The numbers investors will actually watch
The analysis points to a 2026 revenue outlook of US$3.13 billion to US$3.15 billion and almost 2.8 million subscribers as the near-term check on whether this lands. The specific disclosure worth waiting for is peptide subscriber counts or Care+ attachment rates in upcoming earnings commentary.
The same piece flags legal scrutiny and a business mix that can pressure margins as live risks sitting alongside the launch. Compounded therapies have been a regulatory flashpoint for this company before, and a longevity menu does not make that quieter.
What the announcement does not include
No trial, no outcome figure, no published data on any of the five compounds appears anywhere in the coverage. For a program sold on cellular health and longevity, that is a large claim riding on an ingredient list.
It is also worth noting what the source is: a Simply Wall St article produced with AI automation, written for investors rather than patients.
Bottom line
As a business move this is coherent, and the subscription logic is sound. As evidence that peptide-based longevity programs do anything, the launch is not evidence at all, and nothing in the announcement pretends otherwise.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.